Monitor future clinical and commercial strategy updates for signs of accelerated development timelines or partnership activity, as Gilmer's expertise may influence Armata's path to market for its phage-based pipeline. No immediate financial or operational changes are expected from this appointment.
Price Chart
Executive Summary
Armata Pharmaceuticals appointed Dr. Daniel Gilmer, a biopharmaceutical commercial executive with experience at Pfizer and McKinsey, to its Board of Directors. The move adds expertise in commercialization of anti-infectives, including leadership in the U.S. launch of PAXLOVID, to support Armata's development of bacteriophage therapeutics.
Key Facts
- Dr. Daniel Gilmer, Ph.D., appointed to Board of Directors effective April 24, 2026
- Gilmer previously served as Senior Director, Commercial Quality U.S. Team Lead at Pfizer since February 2025
- He led the U.S. launch of PAXLOVID and has experience in commercial strategy, patient access, and antimicrobial resistance
- Gilmer is an equal co-inventor on the patent for Exebacase, a first-in-class bacteriophage lysin
- He will receive an option award to purchase 51,280 shares of common stock, vesting over three years
- No other arrangements or understandings exist with Gilmer beyond standard director compensation
Financial Impact
Minimal immediate financial impact. Director compensation includes $40,000 annual cash retainer and expected option award for 51,280 shares.
Risk Factors
- Integration of new board member may lead to strategic shifts
- No replacement named for any departing executive, indicating potential governance continuity
- Biotech clinical-stage companies face high execution risk in drug development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-048997 |
| Document: tm2612716d1_ex99-1.htm | 0001104659-26-048997 |
| Document: 0001104659-26-048997-index-headers.html | 0001104659-26-048997 |
| Document: 0001104659-26-048997-index.html | 0001104659-26-048997 |
| Document: 0001104659-26-048997.txt | 0001104659-26-048997 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $5.55 $4.26 | ▼ −23.24% | ▼ −23.35% | $3.52 (−36.58%) |
Jul 20, 2026 10w ago | 8-K | $5.06 $4.66 | ▼ −7.91% | ▼ −7.48% | $3.52 (−30.43%) |
May 13, 2026 20w ago | 8-K | $8.20 $8.23 | ▼ −0.37% | ▼ −1.08% | $3.52 (+57.07%) |
Apr 27, 2026 22w ago | 8-K | $11.00 $9.85 | ▼ −10.45% | ▼ −10.85% | $3.52 (−68.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access